| |
Significant patient populations, top clinical institutions, and ease of
regulatory compliance combined to support oncology trial success in APAC. Download our white paper to explore the growth of oncology trials in APAC countries and strategies to support global study success in this dynamic and complex region. Premier Research. Built for Biotech℠ 
|
|
Today's Big NewsOct 26, 2022 |
| By Nick Paul Taylor AstraZeneca has pulled off a pair of wins in breast cancer. After seeing rival drugs from Roche and Sanofi fail, the Anglo-Swedish drugmaker bucked the trend with wins for capivasertib and camizestrant in phase 2 and 3 clinical trials. |
|
|
|
By James Waldron Seres Therapeutics’ SER-109 has faced more setbacks than most therapies, but the biotech has kept the faith and now is tantalizingly close to possibly seeing its candidate become the first FDA-approved oral microbiome therapeutic. |
By Gabrielle Masson Recursion Pharmaceuticals has cut a rare disease asset from its pipeline while pulling in a $150 million private placement and nominating a new cancer program. |
By Nick Paul Taylor Merck KGaA has provided efficacy data from the open-label extension of its phase 2 trial in relapsing multiple sclerosis, delivering evidence of the durability of the effects of the BTK inhibitor evobrutinib. |
By Max Bayer Time BioVentures has closed its first $100 million fund, looking to find the next great biotech hit reminiscent of Silicon Valley success stories. Among the firm's early bets are Elon Musk's neurological medtech company Neuralink. |
By Ben Adams Belgian biotech Bone Therapeutics is no more as the inflammation and cell therapy company transforms into BioSenic. The name change, which comes following the majority buyout of the company’s stock by French biopharma Medsenic, also comes with a ticker change from “BOTHE” to “BIOS” and a new corporate website. |
By Max Bayer In less than a week, Ipsen's rare genetic disorder drug was set to go be reviewed by FDA's independent expert panel, but that timeline is now off. The FDA has requested additional information on clinical trial data for the med, palovarotene, delaying the meeting of the Endocrinologic and Metabolic Drugs Advisory Committee has been postponed. |
By Conor Hale Pacific Biosciences raised the curtain on two DNA sequencers, including its first short-read device—designed to offer new competition to the industry giant Illumina—as well as a machine poised to be an upgrade over its current long-read hardware. |
By Joseph Keenan Symeres has acquired Exemplify BioPharma for an undisclosed price, marking the CRO and CDMO's second purchase in the U.S. company in 2022. |
By Angus Liu Women who are looking to get birth control medication without a prescription will have to wait longer than previously expected. The FDA has pushed back a decision date on a proposed over-the-counter switch of Perrigo’s prescription birth control drug Opill. |
By Heather Landi Starting next year, Florida Blue will use Amazon Pharmacy as its exclusive home delivery service provider for its more than 2 million members covered under individual and employer group-insured plans. |
By Angus Liu After European regulators jumped on a global-first approval for Johnson & Johnson’s BCMA-targeted bispecific drug Tecvayli, the U.S. FDA has doled out its own blessing for the novel therapy. But the U.S. nod covers what appears to be a less favorable treatment setting. |
By Conor Hale At a discussion on the post-pandemic future of diagnostics at AdvaMed’s Medtech Conference in Boston, industry leaders said there is still preparation to be done, and it may be needed sooner rather than later. |
Fierce podcasts Don't miss an episode |
| This week on "The Top Line," we talk about our special report on the top 10 vaccine company rankings. We also report the news on Pfizer's kickback lawsuit, OTC hearing aids and more. |
|
|---|
|
|
|
Wednesday, November 2, 2022 | 1pm ET / 10am PT This webinar will discuss how Invitae and others are working together to characterize the lived experience of patients with rare bile duct cancer, and ultimately, improve patient care. Register now. 
|
|
eBook Improve patient engagement, adherence, and outcomes Sponsored by: Health Catalyst |
Whitepaper Electronic health records (EHR) and patient registries are both important sources of real-world evidence – but which is right for your needs? Sponsored by: Veradigm Health |
eBook Looking to implement a remote patient monitoring (RPM) program at your organization? Download the eBook from Health Catalyst to learn the essential components of successful RPM programs. Sponsored by: Health Catalyst |
eBook In this free guide, explore how Cloud Computing is enabling emerging biopharma organizations to decrease time-to-discovery in pursuit of breakthrough treatment modalities. Sponsored by: RCH Solutions |
eBook With real-world data playing a significant role in health care decisions, life sciences leaders need to maximize their data investments. The best place to start is right here, with our e-book on the four steps to a more coordinated, connected real-world data strategy. Sponsored by: Optum |
Whitepaper Learn the benefits of unlocking data insights across the healthcare and life sciences ecosystem. Sponsored by: NTT DATA |
Whitepaper SaaS LIMS from LabVantage Solutions Is Pre-Validated for Regulated Industries, Delivering Maximum Flexibility, Uptime, and Security. Sponsored by: LabVantage Solutions Inc. |
Whitepaper Read about key factors and trends in RWE and how our data luminaries are the right partner to lead the way forward. Sponsored by: Lumanity |
Whitepaper This paper is the first in a 4-part series focused on developing commercial models for gene therapies Sponsored by: Blue Matter, strategic consultants in the life sciences |
Video Learn how a centralized platform for pathology images, metadata, and analysis results can connect previously siloed research initiatives and advance our collective understanding of tissue. Sponsored by: Proscia |
Video Can an optimized research process--including AI-powered workflow and process automation tools--help get breakthrough drugs to market faster? Sponsored by: Proscia |
Whitepaper What is the most suitable dosage form technology for the Oral Delivery of Lipid-Based Formulations? Sponsored by: Catalent |
Research Learn more about how the versatility of Softgel Technology helped a customer with a volatile compound. Sponsored by: Catalent |
Whitepaper How can Lipid-Based Drug Delivery System help bring poorly soluble drugs to market? Sponsored by: Catalent |
Whitepaper Learn how formulation development for a PFS affects manufacturing to drive the industry toward optimizing delivery of injectable products and, ultimately, improving patient care. Sponsored by: Catalent Biologics |
Webinar Ypsomed and Catalent Biologics experts discuss strategies for integrated PFS manufacturing and auto-injector assembly to accelerate timelines and more in this webinar. Sponsored by: Catalent Biologics |
Custom Resource Center Read through this library of resources to find out how you can strengthen innovation and efficiency, improve safety and quality, and prioritize resources to support your long-term goals. Sponsored by: JLL |
Whitepaper Clarus Therapeutics (Clarus) is a men’s specialty pharmaceutical company that partnered with Catalent to develop a unique and convenient drug delivery form for their hormone replacement therapy. Sponsored by: Catalent |
Whitepaper Learn more about how the transition from early to late phase of a small molecule program plays a pivotal role in a program’s ultimate success. Sponsored by: Catalent |
eBook Orally Inhaled & Nasal Drug Delivery: A Pipeline of Opportunities Sponsored by: Catalent |
Whitepaper Did you know Catalent has newly expanded in-house capabilities spanning clinical and commercial scale manufacturing for DPIs, unit-dose, bi-dose and preserved multi-dose nasal sprays? Sponsored by: Catalent |
Whitepaper What are key considerations for intranasal delivery in the treatment of acute and chronic conditions? Sponsored by: Catalent |
| |
|
